# 2026-19912: 25-year-old drug suspension yanked by FDA at last.

2026-19912, FHTA LLC; Withdrawal of Approval of New Drug Application for MYSOLINE (Primidone) Suspension, 250 Milligrams/5 Milliliters, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-29, effective 2026-09-29; PRIA reads it as touching household money (as of 2026-10-06).

- Canonical: https://policyrisk.com/federal-register/2026-19912
- As of: 2026-10-06
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19912
- Title: FHTA LLC; Withdrawal of Approval of New Drug Application for MYSOLINE (Primidone) Suspension, 250 Milligrams/5 Milliliters
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 61408
- Published: 2026-09-29
- Effective: 2026-09-29
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-06

## In one line

25-year-old drug suspension yanked by FDA at last.

## Summary

The FDA is officially pulling the approval for MYSOLINE (primidone) suspension, a medicine that hasn’t been sold since 2001 due to safety concerns. FHTA LLC, the company behind it, agreed to this withdrawal without a fight. This means MYSOLINE suspension won’t be coming back unless it’s reformulated and proven safe and effective, so patients and pharmacies should look for other options starting September 29, 2026.

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) 010401 for MYSOLINE (primidone) suspension, 250 milligrams (mg)/5 milliliters (mL), held by FHTA LLC (FHTA). FHTA agreed to withdrawal of approval of this application and has waived its opportunity for a hearing.

## Effects PRIA read

- Approval withdrawn for MYSOLINE suspension: cost, low. The FDA withdrew approval of NDA 010401 for MYSOLINE (primidone) suspension, 250 mg/5 mL, effective September 29, 2026. FDA previously found the product was discontinued from sale in 2001 for reasons of safety or effectiveness tied to potential microbial contamination (including Pseudomonas aerugin…
- Interstate distribution now illegal without approval: cost, low. As of September 29, 2026, distribution of MYSOLINE (primidone) suspension, 250 mg/5 mL, into interstate commerce without an approved application is illegal and subject to regulatory action under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)).
- Reformulation and testing required to return: cost, medium. FDA stated that, before MYSOLINE (primidone) suspension, 250 mg/5 mL, could be reintroduced, a reformulation would be required including establishment of preservative content acceptance criteria and correlation with passing antimicrobial effectiveness testing results, and the NDA holder would have…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-19912 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/29/2026-19912/fhta-llc-withdrawal-of-approval-of-new-drug-application-for-mysoline-primidone-suspension-250)
- [2026-19912 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19912.pdf)

## Related
- [Previous: 2026-19911, Modification of Living Organ Donation Reimbursement Program Eligibility Guideli…](https://policyrisk.com/federal-register/2026-19911)
- [Next: 2026-19913, Agency Information Collection Activities: Proposed Collection; Comment Request](https://policyrisk.com/federal-register/2026-19913)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19912 (as of 2026-10-06).
